nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Meropenem solutions should not be frozen. Somewhat paradoxically, while meropenem is designed to resist bacterial enzymes, it can still be broken down by water. Specifically, the amide bond in the β-lactam ring of meropenem makes it resistant to many β-lactamases (penicillinases), which are bacterial enzymes that can break down penicillin and related antibiotics such as meropenem. Meropenem’s resistance is due to the stability of the β-lactam ring, which is less susceptible to hydrolysis by these enzymes. However, meropenem can undergo hydrolysis in aqueous solutions, which can reduce its effectiveness. Hence meropenem requires prolonged slow administration, or frequent re-administration, to continually replace what has been hydrolyzed by the water component of blood. Meropenem is administered every 8 hours. Dosing must be adjusted for altered kidney function and for haemofiltration. Studies describe application of meropenem therapeutic drug monitoring (measurements of drug levels in the bloodstream at specific intervals) for optimal application. As with other β-lactams antibiotics, the effectiveness of treatment depends on the amount of time during the dosing interval that the meropenem concentration is above the minimum inhibitory concentration for the bacteria causing the infection. For β-lactams, including meropenem, prolonged intravenous administration is associated with lower mortality compared to bolus intravenous infusion, especially in severe infections or those caused by less sensitive bacteria, such as Pseudomonas aeruginosa.
Calliphoridae (blowflies) Some examples include Calliphora vomitoria, Calliphora vicina, and Cordylobia Oestridae (botflies) Sarcophagidae (fleshflies) Sarcophaga barbata are usually found in dead and rotting meat and animal excrement, which are prime environments for them. This is because their larvae are facultative parasites, as they feed on organic tissue and use the hosts' oxygen reserve. Other families occasionally involved are:
=== Exercise === Exercise has been shown to improve insulin sensitivity in humans with metabolic syndrome. Increased exercise is therefore recommended in horses with EMS, assuming laminitis does not restrict activity levels. Current recommendations include 2–3 sessions a week, of 20–30 minutes of work, with gradual increase in duration and intensity.
Sources: en.wikipedia.org
In contrast with terrestrial biology, early laboratory studies, including the famous Miller-Urey Experiment, have shown that amino acids may form under a range of possible abiotic conditions with equal (racemic) mixtures of D- and L-enantiomers. Thus, the ratios between enantiomers for a given amino acid may discriminate between biotic and abiotic formation mechanisms. In the first characterisation of amino acids in Murchison, all chiral examples were present in racemic mixtures indicating an abiotic origin. This is consistent with proposed sythetic pathways, as the formation of isovaline and other α-dialkyl amino acids in CM chondrites has been attributed to the Strecker synthesis which produces racemic mixtures of enantiomers.
===== MeSH D08.811.682.660 – oxidoreductases acting on ch-ch group donors ===== MeSH D08.811.682.660.150 – acyl-coa dehydrogenases MeSH D08.811.682.660.150.100 – acyl-coa dehydrogenase MeSH D08.811.682.660.150.150 – acyl-coa dehydrogenase, long-chain MeSH D08.811.682.660.150.200 – acyl-CoA oxidase MeSH D08.811.682.660.150.300 – butyryl-coa dehydrogenase MeSH D08.811.682.660.200 – cholestenone 5alpha-reductase MeSH D08.811.682.660.250 – coproporphyrinogen oxidase MeSH D08.811.682.660.275 – dihydrodipicolinate reductase MeSH D08.811.682.660.300 – dihydroorotate oxidase MeSH D08.811.682.660.325 – dihydrouracil dehydrogenase (nad+) MeSH D08.811.682.660.350 – dihydrouracil dehydrogenase (nadp) MeSH D08.811.682.660.385 – electron transport complex ii MeSH D08.811.682.660.385.500 – succinate dehydrogenase MeSH D08.811.682.660.387 – enoyl-(acyl-carrier-protein) reductase (nadh) MeSH D08.811.682.660.390 – enoyl-(acyl-carrier protein) reductase (nadph, b-specific) MeSH D08.811.682.660.425 – Glutaryl-CoA dehydrogenase MeSH D08.811.682.660.462 – isovaleryl-coa dehydrogenase MeSH D08.811.682.660.490 – 15-oxoprostaglandin 13-reductase MeSH D08.811.682.660.500 – prephenate dehydrogenase MeSH D08.811.682.660.600 – protoporphyrinogen oxidase MeSH D08.811.682.660.750 – succinate dehydrogenase MeSH D08.811.682.660.900 – testosterone 5-alpha-Reductase
Reismanis was an information technology consultant at Accenture and intended to keep ModDB his hobby, but he left the firm to found DesuraNET as the website's hosting company, citing the expense of running the website and his recollection of IGN's 2006 attempt to acquire it. ModDB was integrated into DesuraNET's Desura, which was a digital distribution service that focused on indie games. The service opened in April 2010 as a competitor to Valve's Steam.
That night, an Israeli airstrike on a car in the Beqaa Valley killed two members of the Islamic Group. Targeted assassinations continued the same week with an Israeli airstrike on a car in the village of Kfar Dajjal which killed a Hezbollah member and seriously wounded three children in a nearby school bus. In response, Lebanon issued a formal complaint to the United Nations Security Council. On 25 May, an Israeli airstrike on a truck near the Syrian town of al-Qusayr killed two Hezbollah members. Later that day, a car bombing in Damascus killed a Syrian Army officer with ties to Hezbollah. On 26 May, an Israeli airstrike on a house in Aitaroun killed two Hezbollah members. On the same day, another Hezbollah member was killed, as was another person, following an airstrike on a motorcycle in Naqoura. Later, an airstrike on another motorcycle in Ayta ash Shab killed two civilians. An airstrike on a third motorcycle, in Hula, killed two Hezbollah members and wounded two other people. Two civilians were killed in strikes on the village of Yaroun. On 1 June, an Israeli airstrike on a house in Aadloun killed a civilian and wounded four others. Later that evening, two Israeli airstrikes on a house in Ain Qana killed a Hezbollah member and wounded another person. The next day, an Israeli airstrike on a motorcycle in Hula killed two civilians. On 3 June, a pair of Israeli airstrikes on Naqoura killed two Hezbollah members. Another airstrike, this time on a car near the village of Kauthariyet El Rez, killed another Hezbollah member.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.